Literature DB >> 11298065

Anti-TNF agents for rheumatoid arthritis.

H E Seymour1, A Worsley, J M Smith, S H Thomas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11298065      PMCID： PMC2015031          DOI： 10.1046/j.1365-2125.2001.00321.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  27 in total

Review 1.  Update in rheumatology.

Authors:  R Wernick; S M Campbell
Journal:  Ann Intern Med       Date:  2000-01-18       Impact factor: 25.391

2.  Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.

Authors:  T Möttönen; P Hannonen; M Leirisalo-Repo; M Nissilä; H Kautiainen; M Korpela; L Laasonen; H Julkunen; R Luukkainen; K Vuori; L Paimela; H Blåfield; M Hakala; K Ilva; U Yli-Kerttula; K Puolakka; P Järvinen; M Hakola; H Piirainen; J Ahonen; I Pälvimäki; S Forsberg; K Koota; C Friman
Journal:  Lancet       Date:  1999-05-08       Impact factor: 79.321

3.  Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Authors:  R Maini; E W St Clair; F Breedveld; D Furst; J Kalden; M Weisman; J Smolen; P Emery; G Harriman; M Feldmann; P Lipsky
Journal:  Lancet       Date:  1999-12-04       Impact factor: 79.321

4.  Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis.

Authors:  J R Kirwan; J S Reeback
Journal:  Br J Rheumatol       Date:  1986-05

Review 5.  Adult and juvenile rheumatoid arthritis: current epidemiologic concepts.

Authors:  M C Hochberg
Journal:  Epidemiol Rev       Date:  1981       Impact factor: 6.222

6.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

Authors:  F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra
Journal:  Arthritis Rheum       Date:  1988-03

7.  Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.

Authors:  D J Lovell; E H Giannini; A Reiff; G D Cawkwell; E D Silverman; J J Nocton; L D Stein; A Gedalia; N T Ilowite; C A Wallace; J Whitmore; B K Finck
Journal:  N Engl J Med       Date:  2000-03-16       Impact factor: 91.245

8.  Estimating the incidence of rheumatoid arthritis: trying to hit a moving target?

Authors:  N Wiles; D P Symmons; B Harrison; E Barrett; J H Barrett; D G Scott; A J Silman
Journal:  Arthritis Rheum       Date:  1999-07

9.  Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

Authors:  L W Moreland; M H Schiff; S W Baumgartner; E A Tindall; R M Fleischmann; K J Bulpitt; A L Weaver; E C Keystone; D E Furst; P J Mease; E M Ruderman; D A Horwitz; D G Arkfeld; L Garrison; D J Burge; C M Blosch; M L Lange; N D McDonnell; M E Weinblatt
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

10.  Survival and cause of death in rheumatoid arthritis: a 25-year prospective followup.

Authors:  J P Vandenbroucke; H M Hazevoet; A Cats
Journal:  J Rheumatol       Date:  1984-04       Impact factor: 4.666
View more
  19 in total

1.  Biologic Disease-Modifying Antirheumatic Drugs in a National, Privately Insured Population: Utilization, Expenditures, and Price Trends.

Authors:  Christopher B Atzinger; Jeff J Guo
Journal:  Am Health Drug Benefits       Date:  2017-02

2.  "Cerebral Small Vessel Disease in subclinical and clinical stages, role of inflammation for risk prediction and potential treatment targets, and management strategies".

Authors:  C Frances Fan; José R Romero
Journal:  Intern Med Rev (Wash D C)       Date:  2016-12

3.  A variant of TNFR2-Fc fusion protein exhibits improved efficacy in treating experimental rheumatoid arthritis.

Authors:  Tong Yang; Zheng Wang; Fang Wu; Jingwei Tan; Yijun Shen; Erguang Li; Jingzhi Dai; Ronghai Shen; Gang Li; Jinsong Wu; Luochun Wang; Haibo Wang; Yanjun Liu
Journal:  PLoS Comput Biol       Date:  2010-02-05       Impact factor: 4.475

Review 4.  Preclinical Assessment of Inflammatory Pain.

Authors:  Milind M Muley; Eugene Krustev; Jason J McDougall
Journal:  CNS Neurosci Ther       Date:  2015-12-10       Impact factor: 5.243

5.  Effector memory CD4+ T cells induce damaging innate inflammation and autoimmune pathology by engaging CD40 and TNFR on myeloid cells.

Authors:  Margaret M McDaniel; Amanpreet Singh Chawla; Aakanksha Jain; Hannah E Meibers; Irene Saha; Yajing Gao; Viral Jain; Krishna Roskin; Sing Sing Way; Chandrashekhar Pasare
Journal:  Sci Immunol       Date:  2022-01-21

6.  Influence of Promoter Polymorphisms of the TNF-α (-308G/A) and IL-6 (-174G/C) Genes on Therapeutic Response to Etanercept in Rheumatoid Arthritis.

Authors:  Ivan Jančić; Mirjana Šefik-Bukilica; Slađana Živojinović; Nemanja Damjanov; Vesna Spasovski; Nikola Kotur; Kristel Klaassen; Sonja Pavlović; Biljana Bufan; Nevena Arsenović-Ranin
Journal:  J Med Biochem       Date:  2015-09-19       Impact factor: 3.402

Review 7.  The Role and Impact of Extracellular Vesicles in the Modulation and Delivery of Cytokines during Autoimmunity.

Authors:  Mohammed Tayab Hussain; Asif Jilani Iqbal; Lucy Victoria Norling
Journal:  Int J Mol Sci       Date:  2020-09-26       Impact factor: 5.923

8.  Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure.

Authors:  Joern Kekow; Ulf Mueller-Ladner; Hendrik Schulze-Koops
Journal:  Biologics       Date:  2012-07-02

Review 9.  Temporal cytokine expression and the target organ attributes unravel novel aspects of autoimmune arthritis.

Authors:  Brian Astry; Shivaprasad H Venkatesha; Kamal D Moudgil
Journal:  Indian J Med Res       Date:  2013-11       Impact factor: 2.375

Review 10.  TNF-α Promoter Polymorphisms Predict the Response to Etanercept More Powerfully than that to Infliximab/Adalimumab in Spondyloarthritis.

Authors:  Jing Liu; Zheng Dong; Qi Zhu; Dongyi He; Yanyun Ma; Aiping Du; Fan He; Dongbao Zhao; Xia Xu; Hui Zhang; Li Jin; Jiucun Wang
Journal:  Sci Rep       Date:  2016-08-31       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.